

Margarite D Matossian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6953969/publications.pdf>

Version: 2024-02-01

27
papers

359
citations

933447

10
h-index

839539

18
g-index

29
all docs

29
docs citations

29
times ranked

554
citing authors

#	ARTICLE	IF	CITATIONS
1	Notch Signaling Regulates Mitochondrial Metabolism and NF- κ B Activity in Triple-Negative Breast Cancer Cells via IKK1 \pm -Dependent Non-canonical Pathways. <i>Frontiers in Oncology</i> , 2018, 8, 575.	2.8	64
2	Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models. <i>Breast Cancer Research</i> , 2019, 21, 67.	5.0	45
3	Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs. <i>Molecular Pharmacology</i> , 2019, 96, 272-296.	2.3	30
4	Obesity-Altered Adipose Stem Cells Promote ER+ Breast Cancer Metastasis through Estrogen Independent Pathways. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1419.	4.1	29
5	ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models. <i>Oncotarget</i> , 2018, 9, 6924-6937.	1.8	27
6	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 381-390.	2.5	19
7	Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. <i>BMC Cancer</i> , 2019, 19, 205.	2.6	19
8	Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. <i>Oncoscience</i> , 2018, 5, 99-108.	2.2	15
9	Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. <i>PLoS ONE</i> , 2020, 15, e0226464.	2.5	13
10	ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1164.	2.8	13
11	Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling. <i>Biomolecules</i> , 2021, 11, 183.	4.0	13
12	Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER \pm -negative Breast Cancers to Tamoxifen through ER \pm Reexpression. <i>Molecular Cancer Research</i> , 2017, 15, 1491-1502.	3.4	12
13	NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 49-61.	2.5	10
14	Quantifying Breast Cancer-Driven Fiber Alignment and Collagen Deposition in Primary Human Breast Tissue. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 618448.	4.1	7
15	Multifunctional profiling of triple-negative breast cancer patient-derived tumoroids for disease modeling. <i>SLAS Discovery</i> , 2022, 27, 191-200.	2.7	7
16	Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes. <i>PLoS ONE</i> , 2017, 12, e0177802.	2.5	6
17	Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA β 1 regulation. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 835-850.	2.6	5
18	Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review. <i>Current Medicinal Chemistry</i> , 2021, 28, 6096-6109.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Patient-Derived Xenografts as an Innovative Surrogate Tumor Model for the Investigation of Health Disparities in Triple Negative Breast Cancer. <i>Women S Health Reports</i> , 2020, 1, 383-392.	0.8	4
20	Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment. <i>Oncotarget</i> , 2021, 12, 1110-1115.	1.8	4
21	Diverse and converging roles of ERK1/2 and ERK5 pathways on mesenchymal to epithelial transition in breast cancer. <i>Translational Oncology</i> , 2021, 14, 101046.	3.7	4
22	ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 25-37.	2.5	4
23	Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer. <i>Oncoscience</i> , 2021, 8, 61-71.	2.2	2
24	Concurrent Presentations of Hereditary Spherocytosis and Craniosynostosis Syndromes in Siblings: A Case Series. <i>Clinical Pediatrics</i> , 2021, 60, 151-153.	0.8	1
25	Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells. <i>Oncology Letters</i> , 2021, 21, 380.	1.8	1
26	A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. <i>Anti-Cancer Drugs</i> , 2020, 31, 759-775.	1.4	0
27	Abstract PS16-11: Potential therapeutic effects of HDACi FK228 on TNBC using various models. , 2021, , .		0